Advertisement

Topics

Intarcia Therapeutics, Inc Company Profile

14:11 EDT 23rd June 2018 | BioPortfolio

Intarcia Therapeutics, Inc. is a biopharmaceutical company applying a targeted approach to the acquisition, development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases.

Our highly experienced team uses its expertise in clinical medicine, pharmaceutical development and regulatory affairs to identify and develop new uses or alternative formulations for clinical stage products.

We focus especially on products that have validated mechanisms of action and existing clinical safety and activity data. We frequently combine these products with other products or technologies to create new therapeutic products that address significant market needs. We have applied this approach to create and advance our two lead clinical programs in breast cancer and Hepatitis C.

Location

2000 Powell StreetSuite 1640
Emeryville
California
94608
United States of America

Contact

Phone: (510) 652-2600
Fax: (510) 652-2657
Email: busdev@intarcia.com


News Articles [791 Associated News Articles listed on BioPortfolio]

Intarcia Axes 60, Halts Studies after FDA Clinical Hold

Intarcia Therapeutics has eliminated approximately 60 of its 300 positions--about 20% of its workforce—and terminated two Phase III trials assessing a diabetes drug/device combination following an F...

Biotech unicorn Intarcia cuts staff and stops trials

Intarcia is laying off 60 people, as well as cutting studies of its lead Type 2 diabetes product.

Boston's Intarcia Pink Slips 60 Employees, Terminates Two Late-Stage Trials

A tipster told BioSpace that the layoffs were initially announced by Intarcia CEO Kurt Graves on Jan. 31.

Macrolide Pharma Raises $20M, Names Former Intarcia Exec Karande CEO

Macrolide Pharmaceuticals has a new chief executive to spearhead the company’s antibiotics development efforts, which are now backed by $20 million in fresh capital. Mahesh Karande is taking the hel...

Intarcia terminates Phase III diabetes trials

Intarcia terminates late-stage diabetes trials

Intarcia Therapeutics Inc Medical Equipment Deals and Alliances Profile [Report Updated: 08022018] Prices from USD $250

SummaryIntarcia Therapeutics Inc Intarcia, formerly BioMedicines Inc, is a biopharmaceutical company that discovers, develops and commercializes drug therapies to reduce effects for chronic diseases. ...

Intarcia Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12032018] Prices from USD $250

SummaryIntarcia Therapeutics Inc Intarcia, formerly BioMedicines Inc, is a biopharmaceutical company that discovers, develops and commercializes drug therapies to reduce effects for chronic diseases. ...

PubMed Articles [432 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [144 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1237 Associated Companies listed on BioPortfolio]

Intarcia Therapeutics, Inc.

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the convenience and tolerability of d...

Intarcia Therapeutics, Inc

Intarcia Therapeutics, Inc. is a biopharmaceutical company applying a targeted approach to the acquisition, development and commercialization of novel therapeutic products for the treatment of cancer ...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Intarcia Therapeutics, Inc" on BioPortfolio

We have published hundreds of Intarcia Therapeutics, Inc news stories on BioPortfolio along with dozens of Intarcia Therapeutics, Inc Clinical Trials and PubMed Articles about Intarcia Therapeutics, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Intarcia Therapeutics, Inc Companies in our database. You can also find out about relevant Intarcia Therapeutics, Inc Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record